Nurix Therapeutics Stock - analyst snapshot and weekly review

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 16:36 CET. Details in the imprint.

Nurix Therapeutics (US67079U1007) is trading through a quiet news phase, with no new SEC filings, earnings releases or major press statements emerging over the past day according to US regulatory and company websites.

How analysts view Nurix

Nurix Therapeutics is followed by several US brokerage houses as a clinical-stage biotechnology name listed on Nasdaq under the ticker "NRIX", according to major quote platforms and broker coverage overviews.

Consensus data compiled by financial portals show that most analysts currently rate the stock in the positive band from Hold to Buy, with target prices that imply upside versus recent trading levels, even though exact figures vary by provider and update date.

Weekly review and peer context

For the current week, Nurix shares have been moving in the context of the broader US biotech segment, which has been driven mainly by macro sentiment and sector-specific trial headlines rather than company-specific catalysts for Nurix.

Compared with larger biotechnology benchmarks, Nurix trades as a smaller-cap clinical-stage name, meaning that its shares can react more sharply to trial results or partnership news than diversified large caps and may see periods of muted activity when news is sparse.

The product behind the stock

Nurix Therapeutics focuses on discovering and developing small-molecule medicines that modulate E3 ubiquitin ligases and other components of the body's protein regulation machinery, with an emphasis on oncology and immune disorders as outlined in its corporate materials.

Where the stock trades today

The shares of Nurix Therapeutics (US67079U1007) trade on Nasdaq; the latest verified quote and exact market value are available on major US exchange data pages and may change during today's session.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.